



**Yamhill County**  
**Health and Human Services**  
**Public Health**

# ALERT

**COPY AND DISTRIBUTE TO  
Health Care Providers**

To: Health Care Providers in Yamhill County

From: Yamhill County Public Health

Fax number: (503) 472-9731

Date: **8/17/21**

Regarding: *Monoclonal antibody therapies available in IV and subcutaneous form--now approved for COVID-19 post-exposure prophylaxis*

Phone number for follow-up: **(503) 434-7483**

County healthcare providers,

Please see the message below from OHA's Health Alert Network:

-----

Monoclonal antibodies (mAbs) are recommended for use in high-risk patients for the treatment of mild to moderate, symptomatic COVID-19 confirmed by antigen or PCR testing, within 10 days of onset of illness. Success of treatment is dependent on timing of therapy, with the greatest efficacy seen in patients treated early in the course of illness. NIH and IDSA have published evidence frameworks to support this use based on efficacy data from randomized clinical trials:

[www.covid19treatmentguidelines.nih.gov](http://www.covid19treatmentguidelines.nih.gov)

[www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management](http://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management)

One product (Casirivimab/Imdevimab) is currently available in Oregon through HHS at no charge. **This product is effective against the Delta variant, which is currently the predominant variant circulating in Oregon.** This product is available to ship now, in both **intravenous and subcutaneous** formulations. Casirivimab/Imdevimab has been shown to reduce the risk of hospitalization by 50% (3% treated vs. 6% in the placebo arm) in clinical trials leading to authorization. Subsequent studies have shown a 67% reduction in treated compared to control participants.

Casirivimab/Imdevimab has now been authorized for use as **post-exposure prophylaxis** among individuals exposed to COVID-19 or at high risk for COVID-19 in congregate settings (such as nursing homes and correctional settings), meeting the following criteria:

- Unvaccinated or partially vaccinated

- Fully vaccinated but not expected to mount an adequate immune response— e.g., persons who are immunocompromised or taking immunosuppressive medications

Casirivimab/Imdevimab has been shown to reduce the risk of symptomatic COVID-19 by 81% when used as post-exposure prophylaxis.

Additional information regarding this data is available via the EUA Fact sheet for Healthcare providers. (<https://www.fda.gov/media/145611/download>).

Oregon Health Authority (OHA) encourages providers to consider offering this product to appropriate high-risk patients with COVID-19 infection or exposure to reduce the risk of hospitalization and symptomatic disease, respectively. The subcutaneous formulation can be administered by any qualified personnel in the state of Oregon. Patients who receive this product must be observed for 1 hour following administration because of the rare risk of anaphylaxis. Details on logistics and administration of this new product are available in the updated HHS playbook: <https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Documents/USG-COVID19-Tx-Playbook.pdf>

While these products are available for direct ordering through HHS, please feel free to contact OHA with any questions you may have:

[ORES8.LogisticsChiefs@dhsaha.state.or.us](mailto:ORES8.LogisticsChiefs@dhsaha.state.or.us)